Simtryo (Centanafadine) for ADHD
Simtryo (centanafadine) is a recently FDA-approved, first-in-class triple monoamine reuptake inhibitor (norepinephrine, dopamine, and serotonin) indicated for the treatment of ADHD in both children (6-12 years) and adolescents (13-17 years), as well as adults. 1
Mechanism of Action
Centanafadine represents a novel pharmacological approach distinct from traditional ADHD medications. Unlike amphetamines that actively trigger neurotransmitter release or methylphenidate that selectively blocks dopamine and norepinephrine reuptake, centanafadine inhibits all three monoamine transporters (NET > DAT > SERT) without inducing neurotransmitter release. This mechanism potentially offers sustained efficacy while mitigating the abuse liability, insomnia, and cardiovascular risks typical of traditional psychostimulants. 1
Efficacy Evidence
Adults
In two Phase 3 randomized controlled trials with 446 adults (18-55 years) with moderate to severe ADHD, both 200 mg/d and 400 mg/d centanafadine demonstrated statistically significant improvements in ADHD symptoms at day 42:
- Study 1: Effect sizes of -0.28 (200 mg) and -0.24 (400 mg) versus placebo
- Study 2: Effect sizes of -0.37 (200 mg) and -0.40 (400 mg) versus placebo 2
Long-term data from a 52-week open-label study (n=653) showed ADHD symptom improvements up to 57% from baseline, with 61.4% reporting at least one treatment-emergent adverse event, mostly mild to moderate. 3
Adolescents (13-17 years)
The 328.8 mg dose demonstrated significant efficacy in adolescents, with separation from placebo beginning at week 1 and maintained throughout 6 weeks (p=0.0006). The 164.4 mg dose did not meet the primary endpoint. 4 Additionally, centanafadine improved executive functioning (T-score change: -13.0 vs -8.1 for placebo, p=0.0003) and learning problems (T-score change: -8.0 vs -3.1 for placebo, p<0.0001). 5
Children (6-12 years)
Similar improvements were observed in executive functioning (T-score change: -11.3 vs -6.8 for placebo, p=0.0026) and learning problems (T-score change: -8.2 vs -2.8 for placebo, p<0.0001). 5
Meta-Analysis
A 2026 systematic review of 5 RCTs (n=1,968) confirmed significant reduction in ADHD symptom severity versus placebo (Hedges' g = -0.37,95% CI -0.68 to -0.05; p=0.032), with generally acceptable tolerability. 6
Safety Profile
The most common adverse events include decreased appetite, nausea, headache, insomnia, diarrhea, and rash. 2, 4 Most treatment-emergent adverse events are mild to moderate in severity. The incidence of serious adverse events is low (1.8% in long-term studies), with low abuse potential-related adverse events. 3
Critical caveat: The FDA drug label warnings 7 appear to be for a topical product and are NOT applicable to Simtryo for ADHD—these should be disregarded as they reference external use, wounds, and heating pads, which are irrelevant to oral ADHD medication.
Clinical Positioning
While traditional guidelines recommend stimulants (methylphenidate, amphetamines) or nonstimulants (atomoxetine, guanfacine) as first-line treatments 8, centanafadine offers a novel non-stimulant alternative with a unique triple reuptake mechanism. It is particularly valuable for patients who:
- Have inadequate response to traditional stimulants or nonstimulants
- Experience intolerable side effects from stimulants (insomnia, cardiovascular concerns)
- Have concerns about abuse liability
- Require improvement in executive functioning and learning problems beyond core ADHD symptoms
Dosing Recommendations
Based on the clinical trial evidence:
- Adults: 200-400 mg/day (sustained release formulation, typically divided twice daily)
- Adolescents (13-17 years): 328.8 mg/day (higher dose showed efficacy; lower dose did not meet primary endpoint)
- Children (6-12 years): Specific dosing from pediatric trials not fully detailed in provided evidence, but efficacy demonstrated
Dosing was not titrated in adolescent trials, suggesting fixed-dose administration may be appropriate, though clinical judgment should guide individual patient management. 4